Healthcare communications shop The Ruth Group has launched a new specialized practice dedicated solely to the gene therapy and gene editing sector.
The newly assembled unit, which is currently taking clients, will partner with companies in the gene therapy and gene editing space for the purpose of outlining individual technologies and differentiating each company’s unique aspects.
At least four team members will be dedicated to the focused group. It will be led by senior vice president Robert E. Flamm, Ph.D., and will include staff with scientific, medical and capital markets expertise.
Carol Ruth, TRG founder and president, told O’Dwyer’s that an ongoing rise of gene therapy, personalized medicine and an increased knowledge of the human genome have birthed a number of innovative and growing companies within these spaces, which has similarly driven an increased interest in gene therapy and editing within the communications industry.
“More and more healthcare companies are focusing on applications of these technologies for a variety of indications,” Ruth told O’Dwyer’s. “We formed a specialized group to concentrate on this area due to its unique potential messaging needs and TRG’s unique scientific staff and capabilities. We believe that our group is distinctly qualified and experienced to present the complicated science to the most beneficial audience.”
New York-based TRG, which was founded in 1999, also maintains a Life Sciences and Biotech practice as well as a Medical Devices and Technology division.